| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Imatinib mesylate in cutaneous melanoma. | J Invest Dermatol | 2004 | 1.48 |
| 2 | IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. | Eur J Immunol | 2008 | 1.22 |
| 3 | CD28 aptamers as powerful immune response modulators. | Mol Ther Nucleic Acids | 2013 | 0.98 |
| 4 | Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. | J Invest Dermatol | 2007 | 0.93 |
| 5 | Dendritic cell vaccination in glioblastoma after fluorescence-guided resection. | World J Clin Oncol | 2012 | 0.80 |
| 6 | BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma. | Expert Rev Vaccines | 2011 | 0.75 |